Similarly, triple combination of vorinostat, anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agents in triple-negative breast cancer mouse models resulted in significant increases in anti-tumour activity and overall survival compared to monotherapy [120]. The gene discussed is CTLA4; the disease is triple-negative breast carcinoma.